EA
PTCT icon

Ellsworth Advisors’s PTC Therapeutics PTCT Stock Holding History

Ellsworth Advisors’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-11,529
Closed -$588K – 188
2025
Q1 		$588K Buy
+11,529
New +$575K 0.15% 133
2023
Q3 		– Sell
-7,290
Closed -$296K – 183
2023
Q2 		$296K Buy
7,290
+266
+4% +$13K 0.1% 145
2023
Q1 		$340K Buy
7,024
+330
+5% +$15.1K 0.12% 133
2022
Q4 		$316K Buy
+6,694
New +$278K 0.12% 138

Other funds holding PTCT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ellsworth Advisors's PTCT Position: Q2 2025 in Review

Ellsworth Advisors sold out of PTC Therapeutics (PTCT) in Q2 2025, closing a stake of 11,529 shares — an estimated $588K sold.

Ellsworth Advisors first reported a position in PTCT in Q4 2022 and held it in 4 quarters. The position peaked at $588K in Q1 2025. 283 funds tracked by Wall St. Rank hold PTCT as of Q2 2025.

  • Ellsworth Advisors reported no remaining PTC Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Ellsworth Advisors sold 11,529 PTC Therapeutics shares in Q2 2025, an estimated $588K.
  • Ellsworth Advisors first reported a position in PTC Therapeutics in Q4 2022 and held it in 4 quarters.
  • Ellsworth Advisors's PTC Therapeutics position peaked at $588K in Q1 2025.
  • 283 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2025.

Based on Ellsworth Advisors's 13F filing for Q2 2025, filed 23 Jul 2025.